<DOC>
	<DOCNO>NCT01727830</DOCNO>
	<brief_summary>Aim vitro trial ass effect blood coagulation 60 % dilution different colloid ( HES 130/0.42 , Gelatin Gelatin balance ) investigate reversibility replacement fibrinogen ( FBG ) , factor XIII ( F XIII ) , combination FBG FXIII . In blood 12 volunteer follow measurement perform baseline 60 % dilution HES 130/0.42 , Gelatin Gelatin balance : Blood gas analysis , coagulation factor concentration ( F II , F VII , F VIII , F XIII ) , impedance aggregometry rotational thrombelastometry ( ROTEM® ) . Then FBG , F XIII combination add , concentration correspond 6 g FBG 1250 IU F XIII adult . ROTEM® measurement determination factor concentration perform . - Trial medical device</brief_summary>
	<brief_title>Hemodilution Coagulopathy With 3 Colloids</brief_title>
	<detailed_description />
	<mesh_term>Blood Coagulation Disorders</mesh_term>
	<mesh_term>Hemostatic Disorders</mesh_term>
	<criteria>Inclusion criterion : sign informed consent blood withdrawal Exclusion criterion : know coagulation disorder , form anticoagulation therapy , use acetylsalicylic acid within past five day , use nonsteroidal antiinflammatory agent within past 24 hour , know renal disease plasma concentration aspartate aminotransferase ( &gt; 50 U l 1 ) alanine aminotransferase ( &gt; 50 U l1 ) patient incapable understanding German language</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
</DOC>